Page 248 - Binder2
P. 248
The question now is:
Who will write the rules for the category they’re
creating?
4.9 The Global Access Advantage
If the biologics revolution transformed medicine, it also
exposed its limits.
The most advanced therapies in the world—monoclonal
antibodies, enzyme replacements, immune-modulating
proteins—are routinely out of reach for the majority of the
global population. Not because they don’t work. But
because they can’t be delivered.
They’re too expensive.
Too fragile.
Too infrastructure-dependent.
Biologics, in their current form, are products of the Global
North: industrially manufactured, cold-chain dependent,
and infused in specialty clinics. As a result, most of the
world doesn’t get to participate in the future of medicine.
Edible biologics change that.
Not incrementally.
Fundamentally.
Biologics Without the Biologic Burden
246
